Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer

The unexpected occurrence of thrombotic microangiopathy (TMA), characterised by microangiopathic haemolytic anaemia and thrombocytopenia, in a patient with cancer requires urgent diagnosis and appropriate management. TMA in patients with metastatic cancer can be a manifestation of the malignancy its...

Full description

Bibliographic Details
Published in:	Case Reports in Oncology
Main Authors:	Martin Hausberg, Helmut Felten, Stefan Pfeffer
Format:	Article
Language:	English
Published:	Karger Publishers 2019-01-01
Subjects:	aHUS Atypical Haemolytic Syndrome Bevacizumab Breast cancer Complement Eculizumab Metastases Mitomycin Thrombotic microangiopathy
Online Access:	https://www.karger.com/Article/FullText/495031

Similar Items

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report
by: Xin Wei, et al.
Published: (2024-07-01)

Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022-12-01)

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Case Report with <i>MCP</i> Gene Mutation and Successful Eculizumab Treatment
by: Alex Domínguez-Vargas, et al.
Published: (2024-01-01)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
by: A. Inkeri Lokki, et al.
Published: (2020-04-01)

Thrombotic Microangiopathy with Complement Factor H Gene Mutations Unassociated with Atypical Hemolytic Uremic Syndrome
by: Yesim Oymak, et al.
Published: (2015-07-01)

Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal OutcomesPlain Language Summary
by: Natalja Haninger-Vacariu, et al.
Published: (2023-07-01)

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
by: Elena Román, et al.
Published: (2017-09-01)

Differential diagnosis of thrombotic microangiopathy in nephrology
by: T. Sakari Jokiranta, et al.
Published: (2017-10-01)

“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Federica Maritati, et al.
Published: (2024-04-01)

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
by: Josep M. Campistol, et al.
Published: (2015-09-01)

Posttransplant thrombotic microangiopathy: Unraveling a mystery
by: Mohammed Fahad Khan, et al.
Published: (2024-01-01)

Effective Management of Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma Using Eculizumab
by: Jennifer Kim, et al.
Published: (2025-06-01)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
by: Rachael D. Wright, et al.
Published: (2020-06-01)

Complement Factor H and Complement Factor H-Related Protein 5 Mutations Associated with Atypical Hemolytic Uremic Syndrome in a Systemic Lupus Erythematosus Patient: Efficacy of Eculizumab
by: Sibel ERSAN, et al.
Published: (2019-01-01)

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
by: Saeed AlZabali, et al.
Published: (2022-11-01)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
by: Mustafa N. Yenerel
Published: (2014-08-01)

Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies
by: Quentin Perrier, et al.
Published: (2021-04-01)

Eculizumab therapy on a patient with co‐existent lupus nephritis and C3 mutation‐related atypical haemolytic uremic syndrome: a case report
by: Mi Jung Kim, et al.
Published: (2021-03-01)

Posttransplant thrombotic microangiopathy: Unraveling a mystery
by: Mohammed Fahad Khan, et al.
Published: (2024-01-01)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
by: Everardo Arias Torres, et al.
Published: (2021-03-01)

Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
by: Shreya Agarwal, et al.
Published: (2025-08-01)

Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina
by: Célia Dos Santos, et al.
Published: (2021-05-01)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
by: Palma LMP, et al.
Published: (2016-04-01)

Case Report: Complement-mediated thrombotic microangiopathy masquerading as a pancreatic mass
by: Chuanchuan Sun, et al.
Published: (2026-05-01)

Demographics and baseline disease characteristics of UK patients within the global aHUS registry
by: Rodney D. Gilbert, et al.
Published: (2025-08-01)

Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy
by: Gianluigi Ardissino, et al.
Published: (2022-07-01)

Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study
by: Yoshitaka Tatematsu, et al.
Published: (2024-08-01)

Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review
by: Pilar Musalem
Published: (2025-03-01)

Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center
by: Naama Lax, et al.
Published: (2025-04-01)

A Cell-Based Assay to Measure the Activity of the Complement Convertases
by: Małgorzata Stasiłojć, et al.
Published: (2024-07-01)

New in the differential diagnosis of different variants of thrombotic microangiopathies in obstetrics
by: T. V. Kirsanova, et al.
Published: (2021-04-01)

Living with Atypical Hemolytic Uremic Syndrome in the Netherlands: Patient and Family Perspective
by: Romy N. Bouwmeester, et al.
Published: (2024-07-01)

Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease
by: Cristina Fernández, et al.
Published: (2015-12-01)

Eculizumab in kidney diseases
by: Fatemeh Pour-Reza-Gholi, et al.
Published: (2024-01-01)

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review
by: Dandan Zhang, et al.
Published: (2026-05-01)

Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post–Kidney Transplant: A Case Report
by: Amandeep Godara, et al.
Published: (2020-09-01)

First Successful Therapeutic Plasma Exchange in A 3-Year-5-Month Old Bangladeshi Pae-diatric Patient: A Case Report
by: Tamanna Afroz, et al.
Published: (2020-06-01)

Complement-Inhibiting Therapy of Atypical Haemolytic Uremic Syndrome in a Patient With Factor H Mutation
by: Irina N. Lupan, et al.
Published: (2019-02-01)

The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management
by: Katharina Artinger, et al.
Published: (2019-03-01)

Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy
by: Idris Boudhabhay, et al.
Published: (2021-06-01)